NCT05327647View on ClinicalTrials.gov

A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

June 23, 2022

Primary Completion Date

July 1, 2025

Study Completion Date

December 31, 2026

Conditions
Non-Muscle Invasive Bladder Cancer
Interventions
DRUG

Bicalutamide

Induction intravesical BCG with bicalutamide 150 mg for 90 days

BIOLOGICAL

Control Arm

Induction BCG

Trial Locations (7)

N6A 5W9

RECRUITING

London Health Sciences Centre, London

M5G 2C1

RECRUITING

University Health Network, Princess Margaret Cancer Centre, Toronto

G6V3Z1

RECRUITING

Centre intégré de santé et services sociaux de Chaudière Appalaches, Lévis

H2X 3E4

RECRUITING

Centre Hospitalier de l'Université De Montréal_CHUM, Montreal

H4A 3J1

RECRUITING

McGill University Health Centre_CUSM, Montreal

G1G 5X1

RECRUITING

CHU de Québec-Université Laval, Québec

J1H 5H3

RECRUITING

CIUSSS de l'Estrie - CHUS, Sherbrooke

Sponsors

Collaborators (1)

Cancer Research Society
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Cancer Research Society

OTHER

lead

CHU de Quebec-Universite Laval

OTHER

NCT05327647 - A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter